Table 3 Clinical trials of immunotherapy combined with anti-angiogenic therapy
From: Cold and hot tumors: from molecular mechanisms to targeted therapy
Phase | ICIs Combination Therapy (immune checkpoint) | Doses | [n.treatment] | OS | PFS | Disease | Trial | Status | Ref. |
|---|---|---|---|---|---|---|---|---|---|
II | Atezolizumab (PD-L1) + Bevacizumab (VEGF-A) | atezolizumab (1200 mg) intravenously (i.v.) every 3 weeks | [n = 101] | / | 11.7 m | RCC | NCT01984242 | Completed | |
Atezolizumab (PD-L1)/Sunitinib (VEGFR2, PDGFRβ) | atezolizumab regimen plus bevacizumab (15 mg/kg) i.v. every 3 weeks (n = 101), or sunitinib (50 mg) orally daily 4 weeks on, 2 weeks off. | [n = 101] | / | 6.1 m/8.4 m | |||||
III | Pembrolizumab (PD-1) + Axitinib (VEGFR) | pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily | [n = 432] | / | 15.1 m | RCC | NCT02853331 | Active, not recruiting | |
Sunitinib (VEGFR2, PDGFRβ) | sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle | [n = 429] | 35.7 m | 11.1 m | |||||
III | Atezolizumab (PD-L1) + Bevacizumab (VEGF-A) | atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) of intravenously every 3 weeks | [n = 336] | 19.2 m | 6.8 m | HCC | NCT03434379 | Completed | |
Sorafenib (Raf-1, B-Raf, VEGFR-3) | sorafenib (400 mg) orally twice daily | [n = 165] | 13.4 m | 4.3 m | |||||
II | Pembrolizumab (PD-1) + Lenvatinib (VEGFR2/VEGFR3) | lenvatinib (20 mg) oral daily plus pembrolizumab (200 mg) intravenous every 3 weeks | [n = 29] | / | 7.1 m | Gastric cancer | NCT03609359 | Completed | |
IB/II | Pembrolizumab (PD-1) + Lenvatinib (VEGFR2/VEGFR3) | lenvatinib (20 mg) once daily orally plus pembrolizumab (200 mg) intravenously once every 3 weeks, in 3-week cycles | [n = 108] | 7.4 m | 21.1 m | Endometrial cancer | NCT02501096 | Completed | |
II | Camrelizumab (PD-1) + Apatinib (VEGFR2) + Chemotherapy | camrelizumab (200 mg), liposomal paclitaxel (150 mg/m2), and nedaplatin (50 mg/m2) on day 1, and apatinib (250 mg) on days 1-14 | [n = 30] | 19.43 m | 6.85 m | ESCC | NCT03603756 | Unknown | |
I/II | Camrelizumab (PD-1) + Apatinib (VEGFR2) + Nab-paclitaxel | PD-1 inhibitor (selected according to patients’ requirements) in combination with albumin paclitaxel (125 mg/m2, intravenously, days 1 and 8, or 250 mg/m2, intravenously, day 1) and apatinib (250 or 500 mg, orally, days 1-21) every 3 weeks | [n = 43] | 10.1 m | 6.2 m | Metastatic gastric cancer | NCT04182724 | Unknown | |
III | Avelumab (PD-L1) + Axitinib (VEGFR) | avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily | [n = 442] | 0.59 (95% CI 0.38-0.93) | 0.79 (95% CI 0.53-1.16) | RCC | NCT02684006 | Active, not recruiting | |
Sunitinib (VEGFR2, PDGFRβ) | sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle) | [n = 444] | 0.86 (95% CI, 0.55-1.34) | 1.15 (95% CI 0.77-1.70) |
